Unknown

Dataset Information

0

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.


ABSTRACT: After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differences in baseline characteristics. Rituximab-containing regimens were often prescribed in clinical practice. The most frequently prescribed regimens were fludarabine + cyclophosphamide + rituximab (FCR, 29.3%), bendamustine + rituximab (BR, 17.7%), and other rituximab-containing regimens (22.0%) in the treatment-naïve setting (n = 604), other non-FCR/BR rituximab-containing regimens (38.7%) and non-rituximab-containing regimens (28.5%) in the relapsed/refractory setting (n = 945). Adjusted HRs (95% CI) for progression-free survival (PFS) and overall survival (OS), respectively, with ibrutinib versus real-world regimens were 0.23 (0.14-0.37; p < 0.0001) and 0.40 (0.22-0.76; p = 0.0048) in the treatment-naïve setting, and 0.21 (0.16-0.27; p < 0.0001) and 0.29 (0.21-0.41; p < 0.0001) in the relapsed/refractory setting. When comparing real-world use of ibrutinib (n = 53) versus other real-world regimens in relapsed/refractory CLL (objective 3), adjusted HRs (95% CI) were 0.37 (0.22-0.63; p = 0.0003) for PFS and 0.53 (0.27-1.03; p < 0.0624) for OS. This adjusted analysis, based on nonrandomized patient data, suggests ibrutinib to be more effective than other commonly used regimens for CLL.

SUBMITTER: Salles G 

PROVIDER: S-EPMC6900267 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.

Salles Gilles G   Bachy Emmanuel E   Smolej Lukas L   Simkovic Martin M   Baseggio Lucile L   Panovska Anna A   Besson Hervé H   Healy Nollaig N   Garside Jamie J   Iraqi Wafae W   Diels Joris J   Pick-Lauer Corinna C   Spacek Martin M   Urbanova Renata R   Lysak Daniel D   Hermans Ruben R   Lundbom Jessica J   Callet-Bauchu Evelyne E   Doubek Michael M  

Annals of hematology 20191119 12


After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refractory CLL, comparing patient-level data from two randomized registration trials with two real-world databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differe  ...[more]

Similar Datasets

| S-EPMC9857192 | biostudies-literature
| S-EPMC10832339 | biostudies-literature
| S-EPMC9198904 | biostudies-literature
| S-EPMC9239963 | biostudies-literature
| S-EPMC6899718 | biostudies-literature
| S-EPMC4449150 | biostudies-other
| S-EPMC6966427 | biostudies-literature
| S-EPMC5921964 | biostudies-literature
| S-EPMC6595265 | biostudies-literature